Alternate week and combination intraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil

Medical Mycology

Volumn 40, Issue 5, 2002, Pages 529-534

  Gupta, Aditya K ^a   Taborda, P R ^a   Sanzovo, A D ^a  

^a NONE   (Canada)

Author keywords

Chromoblastomycosis; Combination therapy; Fonsecaea pedrosoi; Itraconazole; Terbinafine; Therapy

Indexed keywords

AMPHOTERICIN B; ANTACID AGENT; ANTIFUNGAL AGENT; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ADULT; ARTICLE; BLOOD CELL COUNT; BRAZIL; CASE REPORT; CHROMOMYCOSIS; CRYOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; ELECTROSURGERY; FEMALE; FONSECAEA PEDROSOI; HUMAN; HYPERTHERMIC THERAPY; LIVER FUNCTION TEST; MALE; MONOTHERAPY; SAFETY; SIDE EFFECT; STOMACH PAIN; TREATMENT OUTCOME; TREATMENT PLANNING;

FONSECAEA; FONSECAEA PEDROSOI;

EID: 0036810547     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.40.5.529.534     Document Type: Article

References (31)

1. Minotto R, Bernardi CD, Mallman LF, et al. Chromoblastomycosis: A review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol 2001; 44: 585-592.
2. Kumarasinghe SP, Kumarsinghe MP. Itraconazole pulse therapy in chromoblastomycosis. Eur J Dermatol 2000; 10: 220-222.
3. Perez A. Terbinafine: Broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases. Mycoses 1999; 42 (Suppl. 2): 111-114.
4. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-179.
5. Iijima S, Takase T, Otsuka F. Treatment of chromomycosis with oral high-dose amphotericin B. Arch Dermatol 1995; 131: 399-401.
6. Yu RY, Gao L. Chromoblastomycosis successfully treated with fluconazole. Int J Dermatol 1994; 33: 716-719.
7. Hiruma M, Kawada A, Yoshida M, et al. Hyperthermic treatment of chromomycosis with disposable chemical pocket warmers. Report of a successfully treated case, with a review of the literature. Mycopathologia 1993; 122: 107-114.
8. Pimentel ER, Castro LG, Cuce LC, et al. Treatment of chromomycosis by cryosurgery with liquid nitrogen: A report on eleven cases. J Dermatol Surg Oncol 1989; 15: 72-77.
9. Pavlidakey GP, Snow SN, Mohs FE. Chromoblastomycosis treated by Mohs micrographic surgery. J Dermatol Surg Oncol 1986; 12: 1073-1075.
10. Silber JG, Gombert ME, Green KM, et al. Treatment of chromomycosis with ketoconazole and 5-fluorocytosine. J Am Acad Dermatol 1983; 8: 236-238.
11. Murray L (ed.) Physician's Desk Reference, Sporanox™ (Itraconazole) Package Insert, 54th edn. Montvale, NJ: Medical Economics Co, 2000: 1547-1560.
12. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989; 14: 110-113.
13. Barchiesi F, Falconi Di Francesco L, et al. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother 1997; 41: 1812-1814.
14. Fothergill AW, Leitner I, Meingassner JG, et al. Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazole. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, USA, September 15-18, 1996. Abstract No. E53, p. 91.
15. Ryder NS, Leitner L. Synergistic interactions of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2000; 39: 91-95.
16. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000; 44: 470-472.
17. Urbina JA, Lazardi K, Aguirre T, et al. Antiproliferative synergism of the allylamine SF86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1988; 32: 1237-1242.
18. Shenep JL, English BK, Kaufman L, et al. Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis 1998; 27: 1388-1393.
19. Sharma NL, Sharma RC, Grover PS, et al. Chromoblastomycosis in India. Int J Dermatol 1999; 38: 846-851.
20. Khalil EA, Nur NM, Zijlstra EE, et al. Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 1996; 90: 187-188.
21. Restrepo A, Gonzalez A, Gomez I, et al. Treatment of chromoblastomycosis with itraconazole. Ann NY Acad Sci 1988; 544: 504-516.
22. Queiroz-Telles F, Purim KS, Fillus JN, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol 1992; 31: 805-812.
23. Sharkey PK, Rinaldi MG, Dunn JF, et al. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991; 35: 707-713.
24. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-308.
25. De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37: 969-974.
26. Gupta AK, Shear NH. Terbinafine: An update. J Am Acad Dermatol 1997; 37: 979-988.
27. Sevigny GM, Ramos-Caro FA. Treatment of chromoblastomycosis due to Fonsecaea pedrosoi with low-dose terbinafine. Cutis 2000; 66: 45-46.
28. Olloagus JM, De Zunita AM, Calero G. Paracoccidioidomycosis (South American blastomycosis) successfully treated with terbinafine: first case report. Br J Derm 2000; 43: 188-191.
29. N'Diaye B, Dieng T, Pérez A, et al. Clinical efficacy of oral terbinafine in fungal mycetoma. Abstract P10-51. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 174.
30. Pérez A, Lamarca A, Vazquez J, et al. High-dose terbinafine to treat fluconazole-resistant oral mucosal candidosis in HIV patients. Abstract P10-53. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 174.
31. Esterre P, Inzan CK, Ratsioharana M, et al. A multicentre trial of terbinafine inpatients with chromoblastomycosis: effect on clinical and biological criteria. J Dermatol Treat 1998; 9 (Suppl 1): 29-34.